Eun-Seok Jeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eun-Seok Jeon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Byung-Kwan Lim
Department of Medicine, Cardiovascular Institute, Samsung Medical Center, Seoul, South Korea
1 shared publicationJae-Ok Shin
From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.
1 shared publicationJong-Mook Kim
From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.
1 shared publicationSeong-Choon Choe
From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.
1 shared publicationSeong-Hyun Ho
From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.
1 shared publicationSeung-Shin Yu
From the Department of Medicine, Cardiovascular Institute, Samsung Medical Center (B.-K.L., J.-O.S., E.-S.J.); Medical Department, MSD Korea Ltd (S.-C.C.); ViroMed Limited, Technology Business Incubator (S.-H.H., J.-M.K., S.-S.Y); and Institute of Molecular Biology and Genetics (S.K.), Seoul National University, Seoul, South Korea.
1 shared publication
Latest Publications
- Open Access
- 19 March 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (11) , 1278-1281
Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis
Background — The inflammatory cytokines have an important role in the pathogenesis of viral myocarditis. Inerleukin-1 (IL-1) is one of the major cytokines that modulate the outcome of viral infection. Among the methods for in vivo gene transfer, direct injection of plasmid DNA is one that is simple and feasible. In this study, we expressed human IL-1 receptor antagonist (hIL-1Ra) in the mouse heart by direct injection of a novel plasmid vector and evaluated its effects on coxsackieviral (CVB3) myocarditis. Methods and Results — A plasmid vector expressing hIL-1Ra (total 40 μg/mouse) was injected into the heart apex of 8-week-old inbred female Balb/C mice (day 3). On day 0, mice (IL-1Ra-CVB3, n=35) were infected intraperitoneally with 10 4 PFU of CVB3; control mice (pCK-CVB3, n=15) were injected with empty vector on day −3 and infected on day 0. hIL-1Ra was expressed in the heart, reached its peak on day 5, and persisted for 2 weeks. The 14-day survival rate of IL-1Ra-CVB3 was higher (77%) than that of controls (30%, P Conclusion — These results showed that direct injection of the expression plasmid vector into the heart was an effective method to transfer the cytokine gene in vivo, and expressed IL-1Ra in the heart can modulate the deleterious effect of the host immune response in viral myocarditis.
- 19 March 2002
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (11) , 1278-1281
Open AccessLocal Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis
Background — The inflammatory cytokines have an important role in the pathogenesis of viral myocarditis. Inerleukin-1 (IL-1) is one of the major cytokines that modulate the outcome of viral infection. Among the methods for in vivo gene transfer, direct injection of plasmid DNA is one that is simple and feasible. In this study, we expressed human IL-1 receptor antagonist (hIL-1Ra) in the mouse heart by direct injection of a novel plasmid vector and evaluated its effects on coxsackieviral (CVB3) myocarditis. Methods and Results — A plasmid vector expressing hIL-1Ra (total 40 μg/mouse) was injected into the heart apex of 8-week-old inbred female Balb/C mice (day 3). On day 0, mice (IL-1Ra-CVB3, n=35) were infected intraperitoneally with 10 4 PFU of CVB3; control mice (pCK-CVB3, n=15) were injected with empty vector on day −3 and infected on day 0. hIL-1Ra was expressed in the heart, reached its peak on day 5, and persisted for 2 weeks. The 14-day survival rate of IL-1Ra-CVB3 was higher (77%) than that of controls (30%, P Conclusion — These results showed that direct injection of the expression plasmid vector into the heart was an effective method to transfer the cytokine gene in vivo, and expressed IL-1Ra in the heart can modulate the deleterious effect of the host immune response in viral myocarditis.